Cristina Fernandez-Carbonell1, David Vargas-Lowy1, Alexander Musallam2, Brian Healy3, Katherine McLaughlin4, Kai W Wucherpfennig4, Tanuja Chitnis5. 1. Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA. 2. Partners MS Center, Brigham and Women's Hospital, Boston, MA, USA. 3. Partners MS Center, Brigham and Women's Hospital, Boston, MA, USA/Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA. 4. Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA, USA. 5. Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA/Partners MS Center, Brigham and Women's Hospital, Boston, MA, USA/Partners Pediatric MS Center, Massachusetts General Hospital, Boston, MA, USA tchitnis@partners.org.
Abstract
OBJECTIVE: To investigate the clinical and magnetic resonance imaging (MRI) features of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-seropositive pediatric demyelinating syndromes. METHODS: Serum samples collected from 74 children with suspected demyelinating disorders whom were being followed at Massachusetts General Hospital were incubated with control green fluorescent protein (GFP)- and MOG-GFP-transfected Jurkat cell clones. The binding ratios were calculated using flow cytometry. Using statistical analyses, we compared the demographic, clinical and radiological features in our seropositive and seronegative patients. RESULTS: We found that 13 out of 74 (17.5%) patients were seropositive for MOG. The MOG-seropositive patients were younger than the seronegative patients (p = 0.049). No single disease category predominated among the seropositive patients, nor was one group more likely to have a polyphasic course. There were two out of four neuromyelitis optica (NMO) patients who had MOG antibodies; both were seronegative for aquaporin -4 (AQP4) antibodies. One had monophasic disease and the other had frequent relapses. There was a bimodal distribution of the MOG-seropositive patients by age at onset, with a distinct younger group (4-8 years) having a high prevalence of encephalopathy and an older group (13-18 years), whom presented almost exclusively with optic neuritis. MRI analysis demonstrated the absence of corpus callosum lesions in the seropositive patients (p = 0.012). The annualized relapse rate (ARR) and the Expanded Disability Status Scale (EDSS) results at 2 years did not differ between the seropositive and seronegative patients. CONCLUSION: MOG antibodies are found across a variety of pediatric demyelinating syndromes having some distinct clinical and MRI features.
OBJECTIVE: To investigate the clinical and magnetic resonance imaging (MRI) features of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-seropositive pediatric demyelinating syndromes. METHODS: Serum samples collected from 74 children with suspected demyelinating disorders whom were being followed at Massachusetts General Hospital were incubated with control green fluorescent protein (GFP)- and MOG-GFP-transfected Jurkat cell clones. The binding ratios were calculated using flow cytometry. Using statistical analyses, we compared the demographic, clinical and radiological features in our seropositive and seronegative patients. RESULTS: We found that 13 out of 74 (17.5%) patients were seropositive for MOG. The MOG-seropositive patients were younger than the seronegative patients (p = 0.049). No single disease category predominated among the seropositive patients, nor was one group more likely to have a polyphasic course. There were two out of four neuromyelitis optica (NMO) patients who had MOG antibodies; both were seronegative for aquaporin -4 (AQP4) antibodies. One had monophasic disease and the other had frequent relapses. There was a bimodal distribution of the MOG-seropositive patients by age at onset, with a distinct younger group (4-8 years) having a high prevalence of encephalopathy and an older group (13-18 years), whom presented almost exclusively with optic neuritis. MRI analysis demonstrated the absence of corpus callosum lesions in the seropositive patients (p = 0.012). The annualized relapse rate (ARR) and the Expanded Disability Status Scale (EDSS) results at 2 years did not differ between the seropositive and seronegative patients. CONCLUSION:MOG antibodies are found across a variety of pediatric demyelinating syndromes having some distinct clinical and MRI features.
Authors: P H Lalive; M G Häusler; H Maurey; Y Mikaeloff; M Tardieu; H Wiendl; M Schroeter; H P Hartung; B C Kieseier; T Menge Journal: Mult Scler Date: 2010-12-22 Impact factor: 6.312
Authors: A K Pröbstel; K Dornmair; R Bittner; P Sperl; D Jenne; S Magalhaes; A Villalobos; C Breithaupt; R Weissert; U Jacob; M Krumbholz; T Kuempfel; A Blaschek; W Stark; J Gärtner; D Pohl; K Rostasy; F Weber; I Forne; M Khademi; T Olsson; F Brilot; E Tantsis; R C Dale; H Wekerle; R Hohlfeld; B Banwell; A Bar-Or; E Meinl; T Derfuss Journal: Neurology Date: 2011-07-27 Impact factor: 9.910
Authors: Kevin C O'Connor; Katherine A McLaughlin; Philip L De Jager; Tanuja Chitnis; Estelle Bettelli; Chenqi Xu; William H Robinson; Sunil V Cherry; Amit Bar-Or; Brenda Banwell; Hikoaki Fukaura; Toshiyuki Fukazawa; Silvia Tenembaum; Susan J Wong; Norma P Tavakoli; Zhannat Idrissova; Vissia Viglietta; Kevin Rostasy; Daniela Pohl; Russell C Dale; Mark Freedman; Lawrence Steinman; Guy J Buckle; Vijay K Kuchroo; David A Hafler; Kai W Wucherpfennig Journal: Nat Med Date: 2007-01-12 Impact factor: 53.440
Authors: D Chabas; J Ness; A Belman; E A Yeh; N Kuntz; M P Gorman; J B Strober; I De Kouchkovsky; C McCulloch; T Chitnis; M Rodriguez; B Weinstock-Guttman; L B Krupp; E Waubant Journal: Neurology Date: 2010-02-02 Impact factor: 9.910
Authors: Katherine A McLaughlin; Tanuja Chitnis; Jia Newcombe; Bettina Franz; Julia Kennedy; Shannon McArdel; Jens Kuhle; Ludwig Kappos; Kevin Rostasy; Daniela Pohl; Donald Gagne; Jayne M Ness; Silvia Tenembaum; Kevin C O'Connor; Vissia Viglietta; Susan J Wong; Norma P Tavakoli; Jerome de Seze; Zhannat Idrissova; Samia J Khoury; Amit Bar-Or; David A Hafler; Brenda Banwell; Kai W Wucherpfennig Journal: J Immunol Date: 2009-08-17 Impact factor: 5.422
Authors: Fabienne Brilot; Russell C Dale; Rebecca C Selter; Verena Grummel; Sudhakar Reddy Kalluri; Muhammad Aslam; Verena Busch; Dun Zhou; Sabine Cepok; Bernhard Hemmer Journal: Ann Neurol Date: 2009-12 Impact factor: 10.422
Authors: Matthias Baumann; Astrid Grams; Tanja Djurdjevic; Eva-Maria Wendel; Christian Lechner; Bettina Behring; Astrid Blaschek; Katharina Diepold; Astrid Eisenkölbl; Joel Fluss; Michael Karenfort; Johannes Koch; Bahadir Konuşkan; Steffen Leiz; Andreas Merkenschlager; Daniela Pohl; Mareike Schimmel; Charlotte Thiels; Barbara Kornek; Kathrin Schanda; Markus Reindl; Kevin Rostásy Journal: J Neurol Date: 2018-02-08 Impact factor: 4.849